SOBI Stock Overview
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SOBI from our risk checks.
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 266.40 |
| 52 Week High | SEK 354.40 |
| 52 Week Low | SEK 241.80 |
| Beta | 0.30 |
| 1 Month Change | -8.77% |
| 3 Month Change | -17.11% |
| 1 Year Change | 3.10% |
| 3 Year Change | 13.89% |
| 5 Year Change | 43.57% |
| Change since IPO | 138.92% |
Recent News & Updates
Recent updates
Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?
Feb 28
Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 07Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet
Jan 21Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Dec 30
Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio
Nov 20 Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next
Oct 27Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 19Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jun 24Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More
May 08Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 27Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Apr 24Shareholder Returns
| SOBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.2% | 1.0% | 6.7% |
| 1Y | 3.1% | -4.6% | -3.4% |
Return vs Industry: SOBI exceeded the Swedish Biotechs industry which returned -5.8% over the past year.
Return vs Market: SOBI exceeded the Swedish Market which returned -6.9% over the past year.
Price Volatility
| SOBI volatility | |
|---|---|
| SOBI Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: SOBI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SOBI's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,806 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology and Specialty Care. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBI fundamental statistics | |
|---|---|
| Market cap | SEK 91.49b |
| Earnings (TTM) | SEK 3.89b |
| Revenue (TTM) | SEK 26.03b |
23.6x
P/E Ratio3.5x
P/S RatioIs SOBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBI income statement (TTM) | |
|---|---|
| Revenue | SEK 26.03b |
| Cost of Revenue | SEK 5.72b |
| Gross Profit | SEK 20.31b |
| Other Expenses | SEK 16.43b |
| Earnings | SEK 3.89b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | 11.31 |
| Gross Margin | 78.03% |
| Net Profit Margin | 14.93% |
| Debt/Equity Ratio | 40.5% |
How did SOBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 08:58 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Xue Chen | Barclays |
| Rosie Turner | Barclays |